Recent developments in receptor tyrosine kinases targeted anticancer therapy

Review (Published online: 29-01-2016)

15. Recent developments in receptor tyrosine kinases targeted anticancer therapy - Samir H. Raval, Ratn D. Singh, Dilip V. Joshi, Hitesh B. Patel and Shailesh K. Mody

Veterinary World, 9(1): 80-90

   doi: 10.14202/vetworld.2016.80-90

Abstract

---

Novel concepts and understanding of receptors lead to discoveries and optimization of many small molecules and antibodies as anti-cancerous drugs. Receptor tyrosine kinases (RTKs) are such a promising class of receptors under the investigation in past three decades. RTKs are one of the essential mediators of cell signaling mechanism for various cellular processes. Transformations such as overexpression, dysregulation, or mutations of RTKs may result into malignancy, and thus are an important target for anticancer therapy. Numerous subfamilies of RTKs, such as epidermal growth factor receptor, vascular endothelial growth factor receptor, fibroblast growth factor receptors, insulin-like growth factor receptor, and hepatocyte growth factor receptor, have been being investigated in recent years as target for anticancer therapy. The present review focuses several small molecules drugs as well as monoclonal antibodies targeting aforesaid subfamilies either approved or under investigation to treat the various cancers.

Keywords: cancer, monoclonal antibodies, small molecule drugs, receptor tyrosine kinases, targeted therapy.